BLI Stock Price, News & Analysis

On April 17, 2023, PhenomeX (Nasdaq: CELL) unveiled its new Opto® T Cell Profiling workflow, designed to enhance the characterization of T cells for immunotherapy development. This innovative technology allows for the comprehensive profiling of single T cells, linking their polyfunctionality with cytotoxicity, which is crucial for identifying potent anti-tumor agents. The Optofluidic Platforms utilize opto-electropositioning to isolate T cells in NanoPen chambers, facilitating advanced assays that enable researchers to correlate cytokine secretion and gene sequences. The company showcased these advancements at the AACR Annual Meeting 2023 in Orlando, Florida, highlighting their commitment to revolutionizing cancer research. The new workflow promises to empower scientists with deeper insights into cell function, significantly impacting the future of immunotherapy.

PhenomeX (Nasdaq: CELL) announced the appointment of Peter Silvester to its board of directors, effective immediately. Silvester, who has over 25 years of experience in the life sciences industry, previously served as senior vice president and president of Life Sciences Solutions for Thermo Fisher Scientific. His expertise spans critical areas such as mergers and acquisitions, commercial operations, and finance.

CEO Siddhartha Kadia emphasized that Silvester's extensive knowledge and insights will be pivotal as PhenomeX seeks to lead in functional cell biology. Silvester will sit on the Audit and Compensation & Leadership Development Committees. His addition comes at a significant time for PhenomeX, which aims to empower scientists and enhance disease treatment through innovative solutions.

PhenomeX Inc. (Nasdaq: CELL) announced its participation in the AACR Annual Meeting 2023 from April 14-19 in Orlando, Florida. The conference focuses on advancements in cancer science and medicine, highlighting the theme "Advancing the Frontiers of Cancer Science and Medicine." PhenomeX, formed from the merger of Isoplexis and Berkeley Lights (Nasdaq: BLI), will showcase its IsoSpark and Beacon® optofluidic platform technologies at booth #3444. Attendees can see demonstrations and learn about applications that provide insights into cell function relevant to scientific discovery, bioprocessing, and clinical research. Additionally, PhenomeX technologies will feature in nine poster presentations covering various cancer research topics.

Berkeley Lights, Inc. has completed its acquisition of IsoPlexis Corporation, leading to the formation of PhenomeX. Trading under the ticker CELL, this newly merged entity aims to be a leader in life sciences solutions. The merger is expected to deliver $70 million in cost synergies and boost profitability as it targets a growing market for functional cell biology. In 2022, the combined revenue was approximately $95 million, with a significant installed base of instruments in major pharmaceutical companies and cancer centers. Share distribution post-merger shows Berkeley Lights shareholders owning roughly 75.2% of PhenomeX.

Berkeley Lights, Inc. (BLI) reported its financial results for Q4 and FY 2022, revealing an 8% decline in annual revenue to $78.6 million. Q4 revenue was $17.8 million, down from $23.2 million in 2021. The company's gross profit for FY 2022 was $53.8 million, with a gross margin of 68%. Operating expenses surged to $151.8 million, resulting in a net loss of $98 million. Despite these challenges, Berkeley Lights announced its planned acquisition of IsoPlexis to enhance its market position and accelerate future growth, aiming for positive cash flow by the end of 2024. No revenue guidance for 2023 was provided, pending the acquisition's completion.

Berkeley Lights, Inc. (Nasdaq: BLI) will report its fourth quarter and full year 2022 financial results on February 23, 2023, after market close. A conference call will be held at 1:30 PM PT (4:30 PM ET) to discuss these results. The webcast will be accessible in the Investors section of their website and will be archived for later listening.

Berkeley Lights specializes in life sciences tools that accelerate the commercialization of biotherapeutics and cell-based products. Their platform provides extensive data on single cells, aiming to set an industry standard.

Berkeley Lights (Nasdaq: BLI) announced preliminary results showing 2022 revenue between $78.0 million and $78.5 million, down from $85.4 million in 2021. This decline is attributed to delays in deploying the Beacon® platform and reduced income from partnerships. The company noted a tightening macroeconomic environment impacting sales cycles and budgets. CEO Siddhartha Kadia emphasized ongoing plans to launch new Beacon platforms and the acquisition of IsoPlexis, aiming for a stronger product mix and positive cash flow by 2024.

Berkeley Lights, Inc. (Nasdaq: BLI) has launched the Beacon Select, a new two-chip, single-cell optofluidic system aimed at enhancing cell line development (CLD) for small- to mid-sized biopharma and CDMOs/CROs. This system builds on the original Beacon technology, offering a more affordable option for new users. With a list price approximately half that of the original Beacon, it enables high throughput cloning and screening within days. Customers can choose from flexible purchase options, increasing accessibility and lowering total costs for cell line development.